PRODUCT

°í°´¸¸Á·À» À§ÇØ Áö¼ÓÀûÀ¸·Î °í¹ÎÇϰí Çõ½ÅÇÏ¿© ÃÖ°íÀÇ Ç°ÁúÀ» Á¦°øÇÕ´Ï´Ù.

R&D reagents

Product > R&D reagents
Benztropine mesylate, 98%
CAS No V2115-1g
Á¦Ç°¹øÈ£ AK Sci.(USA)
Á¦Á¶»ç ¼öÀÔ»ê
Àç°í 1 EA
±Ý¾× 37,000¿ø
Æ÷Àå´ÜÀ§






¡Ø È­Çиí : Benztropine mesylate, 98%

 

¡Ø µî±Þ : APIs and Bioactives > AChR Agonists

 

¡Ø ÆÇ¸Å Æ÷Àå´ÜÀ§ : 1g , 5g

 

¡Ø È­ÇÐ½Ä : C21H25NO.CH4O3S

 

¡Ø CAS # : [132-17-2]

 

 

IDENTITY
CAS Registry #:

 

[132-17-2]

MDL Number: MFCD00074784
MF: C21H25NO.CH4O3S
MW: 403.535
EINECS: 205-048-8
SPECIFICATIONS & PROPERTIES
Purity: 98%
Physical Form: White to off-white powder
Melting Point: 133-135¡ÆC
Long-Term Storage:

 

Store long-term at 2-8¡ÆC

Shipping: Regulated for Shipping
UN #: 2811
Hazard Class: 6.1
Packing Group: III

BIOLOGICAL INFO
Application(s): Dopamine transporter (DAT) inhibitor

REVIEW

Benztropine is a selective M1 muscarinic acetylcholine receptor antagonist. It is able to discriminate between the M1 (cortical or neuronal) and the peripheral muscarinic subtypes (cardiac and glandular). Benztropine partially blocks cholinergic activity in the CNS, which is responsible for the symptoms of Parkinsons disease. It is also thought to increase the availability of dopamine, a brain chemical that is critical in the initiation and smooth control of voluntary muscle movement.

REFERENCES
[1] Wszola BA, Newell KM, Sprague RL: Risk factors for tardive dyskinesia in a large population of youths and adults. Exp Clin Psychopharmacol. 2001 Aug;9(3):285-96.
[2] van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS: Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry. 1998 Apr;155(4):565-7.

Risk Description(s)
R23/24/25: Toxic by inhalation, in contact with skin and if swallowed

Safety Description(s)
S36/37/39: Wear suitable protective clothing, gloves and eye/face protection.
S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).